Clinical Developments for the EGFR-TKI Combined with Radiotherapy in Advanced Non-small Cell Lung Cancer
10.3779/j.issn.1009-3419.2014.04.12
- VernacularTitle:EGFR-TKI联合放疗治疗晚期非小细胞肺癌的研究进展
- Author:
LI XIANAN
1
;
ZHU GUANGYING
Author Information
1. 北京大学人民医院
- Keywords:
EGFR-TKI;
Radiotherapy;
Lung neoplasms
- From:
Chinese Journal of Lung Cancer
2014;(4):357-362
- CountryChina
- Language:Chinese
-
Abstract:
Lung cancer is one of the most common malignant tumor in the world, severely threatening human life. Recently, targeted therapy such as the epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) made huge progress in treatment of lung cancer. EGFR-TKIs, with its high selectivity and low toxicity, is the ifrst choice for EGFR-mutated patients in stage IV non-small cell lung cancer (NSCLC). However, secondary drug resistance becomes a clinical problem to be urgently resolved. In recent years, a series of preclinical studies showed that EGFR-TKI can enhance the antitumor activ-ity of ionizing radiation. hTerefore, EGFR-TKI combined with radiation is extremely promising therapy pattern for advanced NSCLC. hTis review will discuss the research status in EGFR-TKI and radiotherapy for advanced NSCLC.
